Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The company is headquartered in Radnor, Pennsylvania.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-171.45M |
| Operating Margin | 0.00% |
| Return on Equity | -31.00% |
| Return on Assets | -21.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.74 |
| Price-to-Book | 3.82 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -7.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $88.16M |
| Float | $61.86M |
| % Insiders | 0.66% |
| % Institutions | 107.11% |
Volatility is currently contracting
Mineralys Therapeutics, Inc. (MLYS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.
RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions.
– Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met –
RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Jefferies 2026 Global Healthcare Conference being held in New York on June 2-4, 2026.
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –
Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Mineralys is downgraded from 'Strong Buy' to 'Hold' due to competitive and clinical setbacks. MLYS's lorundrostat NDA was accepted by the FDA with a PDUFA date of December 22, 2026, targeting uncontrolled/resistant hypertension. Failure to meet the primary endpoint in the OSA hypertension subpopulation and AstraZeneca's earlier PDUFA for baxdrostat create significant headwinds.
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript
– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
